Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Landscape & Forecast – Disease Landscape & Forecast
The launch of several novel therapies and multiple label expansions for premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL) therapy market. Key therapies that we expect to fuel growth are the CAR T-cell therapies Yescarta (Gilead), Kymriah (Novartis), Tecartus (Gilead), and Breyanzi (Bristol Myers Squibb) as well as the targeted agents Polivy (Roche), Monjuvi / Minjuvi (MorphoSys / Incyte), Tazverik (Epizyme), Brukinsa (BeiGene), and Zynlonta (ADC Therapeutics); also, approval of bispecific antibodies Lunsumio (Roche), Epkinly / Tepkinly (Genmab / AbbVie), and Columvi (Roche) will drive growth. We also expect the noncovalent BTK inhibitor Jaypirca (Loxo Oncology / Eli Lilly) for CLL / SLL and combinations incorporating Imbruvica (Janssen / AbbVie), Calquence (AstraZeneca), and Venclexta / Venclyxto (AbbVie / Roche) to enter the CLL market, causing a shift away from conventional immunochemotherapy regimens. Notably, the anticipated launch of other bispecific antibody—odronextamab (Regeneron Pharmaceuticals), antibody-drug conjugate brentuximab vedotin (Seagen) etc. will further fragment the FL, CLL / SLL, DLBCL, and MCL patient settings, creating intense competition.
Questions Answered
- What is the size of clinically and commercially relevant drug-treatable NHL / CLL populations, and how will drug-treatment rates change over the 2022-2032 forecast period, by geography?
- What is the market impact of label expansions of CAR T-cell therapies in earlier lines of R/R DLBCL? What is the expected market impact of other drug approvals in various NHL / CLL patient populations?
- Which emerging therapies are the most promising in NHL / CLL, and what patient populations will they target?
- What factors are driving growth in the NHL / CLL market? Which drug class will dominate the treatment of NHL / CLL?
Content Highlights
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 19 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.
Epidemiology: Diagnosed incidence of NHL by country; drug-treatable and drug-treated cases segmented by subtype (follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia / small lymphocytic leukemia) and line of therapy.
Population segments in market forecast: First-line, second-line, third-line, and fourth-line for FL, CLL / SLL, DLBCL, and MCL.
Emerging therapies: Phase III / PR: 4+ drugs.
Product Description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Key findings
- Market share of drug classes for NHL / CLL: 2022
- Market share of drug classes for NHL: 2032
- Drug-treatable population share and major-market sales share for CLL / SLL: 2022
- Drug-treatable population share and major-market sales share for CLL / SLL: 2032
- Drug-treatable population share and major-market sales share for DLBCL: 2022
- Drug-treatable population share and major-market sales share for DLBCL: 2032
- Drug-treatable population share and major-market sales share for FL: 2022
- Drug-treatable population share and major-market sales share for FL: 2032
- Drug-treatable population share and major-market sales share for MCL: 2022
- Drug-treatable population share and major-market sales share for MCL: 2032
- Population positioning of current therapies in NHL
- Population positioning of emerging therapies in NHL
- NHL SWOT analysis
- Market drivers and constraints
- Segment-specific trends
- Key findings
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Key findings
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for NHL
- Current treatments used for NHL
- Market events impacting the use of key current therapies in NHL
- Monoclonal antibodies
- Antibody-drug conjugates
- Apoptosis-inducing agents
- Immunomodulatory agents
- Proteasome inhibitors
- BTK inhibitors
- PI3K inhibitors
- Cytotoxic agents
- CAR T-cell therapies
- Immune checkpoint inhibitors
- EZH2 inhibitors
- Selective inhibitors of nuclear export
- Bispecific antibodies
- Medical practice
- First-line CLL / SLL drug-treatable population
- First-line DLBCL drug-treatable population
- First-line FL drug-treatable population
- First-line MCL drug-treatable population
- Relapsed / refractory CLL / SLL drug-treatable population
- Relapsed / refractory DLBCL drug-treatable population
- Relapsed / refractory FL drug-treatable population
- Relapsed / refractory MCL drug-treatable population
- Patient characteristics influencing drug selection in NHL
- Region-specific treatment practices
- Key findings
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Access & Reimbursement Overview
- Methodology
- Appendix
Priyanka Sharma, M.B.A., Healthcare Research & Data Analyst, Oncology. Prior to joining this company, she was a knowledge management consultant with ZS Associates, where she was responsible for designing and conducting secondary research on disease markets and providing end-to-end support to pharmaceutical clients during products’ life cycle. She also worked at DelveInsight Business Research, where she conducted pharmaceutical market forecasting in multiple therapy areas for various clients. She holds a bachelor’s degree in pharmacy and an M.B.A. in pharmaceutical management from the University Institute of Applied Management Sciences at Panjab University in Chandigarh, India.
Harinder Kumar, B.D.S., M.P.H., is an associate epidemiologist at Clarivate. His areas of interest are cancer and psychiatric epidemiology. Previously, Dr. Kumar worked with the government of Punjab, National Health Mission, India. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai. He holds a B.D.S. in dentistry from the National Dental College and Hospital in Punjab.